Aim: To report the role of different imaging methods in staging individuals with multiple endocrine neoplasia 2A (MEN2A) or familial medullary thyroid carcinoma (FMTC). Material and Methods: Fourteen newly diagnosed gene carriers underwent cervical ultrasound scanning (US), cervical and mediastinal CT, MRI and whole-body meta-iodobenzylguanidine (MIBG) scintigraphy and [18F]fluorodeoxyglucose (FDG) PET scanning. Results: US identified seven true primary cancer. CT and MRI located only tumors ≥ 5 mm in diameter. MIBG scintigraphy and FDG PET could not identify MTC foci within the thyroid. Whole-body FDG PET identified two true-positive and one false-positive lymph node metastases. MIBG scintigraphy did not identify lymph node metastases. Total thyroidectomy was performed in 12 cases, and subtotal thyroidectomy in two subjects. Conclusions: Whole-body FDG PET and cervical US help stage individuals carrying mutant genes verifying MEN2A or FMTC.
- Familial medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
- Positron emission tomography
- RET proto-oncogene
ASJC Scopus subject areas